Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
See floor plan attached
Synairgen have paid the big bucks for a 20' square patch (second from right middle row below Pfizer)
https://www.freemanco.com/forms/504944/target_floor_plan.pdf
Hall F has 28' ceilings in 138,780 square feet of space.
It will be a 2 hour session walking from stall to stall by people in the industry, good clear presentation of data is a must in this environment - hopefully a good number have circled P314 on their brochure and the 12 staff are kept busy answering questions and drumming up interest.
Flicking through some of the other 60 odd presenters many seem to be very specific (Hiccups in a man with covid)
Also cant find any other embargoed abstracts - RNS prior surely
Hi Brand,
Investopedia gave this nice example for CI
Assume the interval (height of BB plyers) is between 72 inches and 76 inches (mean 74). If the researchers take 100 random samples from the population of high school basketball players as a whole, the mean should fall between 72 and 76 inches in 95 of those samples.
What the values of 0.3335 and 0.9376 represent I don't know, but I do know they are points either side of the mean on a bell shaped distribution curve - the values that fall in this range represent 95% of the sample.
Manifesto, of course what you have said is correct though we've been disappointed with presentations in the past so I wouldn't be too shocked with another kick in the balls.
The data we are expecting will be presented at ATS are in essence beer tokens to be spent at the last chance saloon.
Don't really see where we go if there is no positive to be drawn from the three branches of data we've all outlined.
Doc I used to be a teacher (not a great one) and we termed a phrase of 'door handle planning' - basically getting to a lesson having about as much of an idea what will be taught in the next hour as the kids. Sometimes it was gold, predictably often it was guff.
I wonder if SNG go by this mantra and as such I expect an RNS the morning after the ATS conference after they've stood in front of the audience and said whatever guff / gold pops into their head ;-)
Brand, Aether, Is it possible this is simply a new requirement for all medical imports ?
The banner of the page reads:
"Alpha Release This is a new service - your feedback will help improve it."
Do we know if AmegaBiotech supplied the product for the trial doses to date, surely they would need to go through the same hoops to import product for trialling also ?
I found it strange that they (AmegaBiotech) use a trading name of a company (Zelltek) they swallowed in 2005 (!)
Prion, I agree with you but can't see any point in selling up now !
I don't really understand why the NIH are holding onto A2 data for so long, if the data was crap would they have shared it quicker ? Are they trying to find a situation for a further trial themselves ?
Either way would be nice if they threw us a bone before long !
The stuff dreams are made of Tommy !
I think I bought into the Polygon want a quick resolution perspective and not so sure now.
Everything crossed for some decent signals from the deep dive / long covid data and a relatively quick end game.
https://www.investegate.co.uk/polygon-glbl-prtnrs/rns/offer-update/202108230732424445J/
This makes interesting reading, flies in the face of suggestions Polygon want a quick resolution - in this instance it looks like they were happy to be patient, grind the shareholders into the dirt, offer rock bottom s.p for buyout with a threat of further delay and litigation. gulp !